Quentis Therapeutics Overview
- Founded
-
2015
- Status
-
Out of Business
- Employees
-
16
- Latest Deal Type
-
Out of Business
Quentis Therapeutics General Information
Description
Developer of immuno-therapeutics designed to translate novel biology into new therapeutic approaches. The company's therapeutics are designed to target endoplasmic reticulum (ER) stress pathways and awaken the immune system's ability to fight the tumor, enabling patients to boost anti-tumor immunity in cancer
Contact Information
Website
www.quentistx.com
Formerly Known As
Quentis, Inc.
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Primary Office
- 430 East 29th Street
- Suite 1005
- New York, NY 10016
- United States
+1 (646) 000-0000
Quentis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 24-Mar-2022 | 000.00 | Completed | Out of Business | ||
| 4. Grant | 03-Dec-2018 | 000 | 000.00 | Completed | Product Development | |
| 3. Early Stage VC (Series A) | 27-Feb-2018 | 000.00 | 000.00 | 000.00 | Completed | Product Development |
| 2. Seed Round | 22-Nov-2017 | $2M | $5M | 0000 | Completed | Startup |
| 1. Seed Round | 09-Jun-2016 | $3M | $3M | 000 | Completed | Startup |
Quentis Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Seed | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
Quentis Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of immuno-therapeutics designed to translate novel biology into new therapeutic approaches. The company's ther
Drug Discovery
New York, NY
16
As of 2018
000.00
00000000 00
000.00
0000 0
mod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerci
0000 000000000
Cambridge, MA
00
As of 0000
00000
00000000
00000
000000
abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000000000000
Paris, France
0
As of 0000
00000
00000000
00000
Add Comparison
Quentis Therapeutics Competitors (70)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 0000000000 | Formerly VC-backed | Paris, France | 0 | 00000 | 00000000 | 00000 |
| 000000000 00000000 | Venture Capital-Backed | Rockville, MD | 0 | 000.00 | 0000000000 0 | 000.00 |
| 000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 0000000 | Corporate Backed or Acquired | San Diego, CA | 0 | 00000 | 000000&0 | 00000 |
Quentis Therapeutics Patents
Quentis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3548476-A1 | Ire1 small molecule inhibitors | Pending | 02-Dec-2016 | 0000000000 | |
| EP-3548476-A4 | Ire1 small molecule inhibitors | Pending | 02-Dec-2016 | 0000000000 | 0 |
| US-20190276434-A1 | Ire1 small molecule inhibitors | Active | 02-Dec-2016 | 0000000000 | |
| CA-3044259-A1 | Ire1 small molecule inhibitors | Pending | 02-Dec-2016 | 0000000000 | |
| US-10934275-B2 | Ire1 small molecule inhibitors | Active | 02-Dec-2016 | C07D401/14 |
Quentis Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
